Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Relevance of MIC-1 in the Era of PSA as a Serum Based Predictor of Prostate Cancer: A Critical Evaluation.

Bansal N, Kumar D, Gupta A, Chandra D, Sankhwar SN, Mandhani A.

Sci Rep. 2017 Dec 4;7(1):16824. doi: 10.1038/s41598-017-17207-2.

2.

Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study.

Young GJ, Harrison S, Turner EL, Walsh EI, Oliver SE, Ben-Shlomo Y, Evans S, Lane JA, Neal DE, Hamdy FC, Donovan JL, Martin RM, Metcalfe C.

BMJ Open. 2017 Oct 30;7(10):e017729. doi: 10.1136/bmjopen-2017-017729.

3.

Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer.

An JY, Sidana A, Choyke PL, Wood B, Pinto PA, Türkbey İB.

Balkan Med J. 2017 Sep 29;34(5):388-396. doi: 10.4274/balkanmedj.2017.0708.

4.

Prostate cancer screening in a low prevalence population. Is it worth it?

Arafa MA, Farhat KH, Al-Atawi MA, Rabah DM.

Saudi Med J. 2017 Jul;38(7):733-737. doi: 10.15537/smj.2017.7.18643.

5.

Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.

Mühlberger N, Boskovic K, Krahn MD, Bremner KE, Oberaigner W, Klocker H, Horninger W, Sroczynski G, Siebert U.

BMC Public Health. 2017 Jun 26;17(1):596. doi: 10.1186/s12889-017-4439-9.

6.

Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study.

Hoffman RM, Lo M, Clark JA, Albertsen PC, Barry MJ, Goodman M, Penson DF, Stanford JL, Stroup AM, Hamilton AS.

J Clin Oncol. 2017 Jul 10;35(20):2306-2314. doi: 10.1200/JCO.2016.70.6317. Epub 2017 May 11.

PMID:
28493812
7.

Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort.

Bhindi A, Bhindi B, Kulkarni GS, Hamilton RJ, Toi A, van der Kwast TH, Evans A, Zlotta AR, Finelli A, Fleshner NE.

Can Urol Assoc J. 2017 Jan-Feb;11(1-2):41-46. doi: 10.5489/cuaj.4031.

8.

Germline genetic profiling in prostate cancer: latest developments and potential clinical applications.

Ahmed M, Eeles R.

Future Sci OA. 2015 Dec 18;2(1):FSO87. doi: 10.4155/fso.15.87. eCollection 2016 Mar. Review.

9.

Primary care providers' cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda.

Hamilton JG, Abdiwahab E, Edwards HM, Fang ML, Jdayani A, Breslau ES.

J Gen Intern Med. 2017 Mar;32(3):315-324. doi: 10.1007/s11606-016-3943-4. Epub 2016 Dec 19.

PMID:
27995427
10.

Similar perspectives on prostate cancer screening value and new guidelines across patient demographic and PSA level subgroups: A qualitative study.

Partin MR, Lillie SE, White KM, Wilt TJ, Chrouser KL, Taylor BC, Burgess DJ.

Health Expect. 2017 Aug;20(4):779-787. doi: 10.1111/hex.12517. Epub 2016 Nov 2.

11.

Metabolomics and its Application to the Development of Clinical Laboratory Tests for Prostate Cancer.

McDunn JE, Stirdivant SM, Ford LA, Wolfert RL.

EJIFCC. 2015 Mar 10;26(2):92-104. eCollection 2015 Mar.

12.

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa).

Stephan C, Rittenhouse H, Hu X, Cammann H, Jung K.

EJIFCC. 2014 Apr 28;25(1):55-78. eCollection 2014 Apr.

13.

Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, Blazeby JM, Peters TJ, Holding P, Bonnington S, Lennon T, Bradshaw L, Cooper D, Herbert P, Howson J, Jones A, Lyons N, Salter E, Thompson P, Tidball S, Blaikie J, Gray C, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Davis M, Turner EL, Martin RM, Neal DE; ProtecT Study Group*.

N Engl J Med. 2016 Oct 13;375(15):1425-1437. doi: 10.1056/NEJMoa1606221. Epub 2016 Sep 14.

14.

Prostate cancer screening in Brazil: should it be done or not?

Busato WF Jr, Almeida GL.

Int Braz J Urol. 2016 Nov-Dec;42(6):1069-1080. doi: 10.1590/S1677-5538.IBJU.2015.0709. Review.

15.

Prostate MRI - an update for the referring urologist.

Czarniecki M, Jakuciński M, Królicki L.

Cent European J Urol. 2016;69(2):162-9. doi: 10.5173/ceju.2016.708. Epub 2016 Jan 22. Review.

16.

Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and prevention.

Izzotti A, Carozzo S, Pulliero A, Zhabayeva D, Ravetti JL, Bersimbaev R.

Am J Cancer Res. 2016 Jul 1;6(7):1461-93. eCollection 2016. Review.

17.

Patient and Physician Factors Associated with Undisclosed Prostate Cancer Screening in a Sample of Predominantly Immigrant Black Men.

Lepore SJ, Nair RG, Davis SN, Wolf RL, Basch CE, Thomas N, Shmukler C, Ullman R.

J Immigr Minor Health. 2017 Dec;19(6):1343-1350. doi: 10.1007/s10903-016-0468-1.

PMID:
27449217
18.

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.

Lane A, Metcalfe C, Young GJ, Peters TJ, Blazeby J, Avery KN, Dedman D, Down L, Mason MD, Neal DE, Hamdy FC, Donovan JL; ProtecT Study group.

BJU Int. 2016 Dec;118(6):869-879. doi: 10.1111/bju.13582. Epub 2016 Aug 17.

19.
20.

Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.

Chen H, Liu X, Brendler CB, Ankerst DP, Leach RJ, Goodman PJ, Lucia MS, Tangen CM, Wang L, Hsu FC, Sun J, Kader AK, Isaacs WB, Helfand BT, Zheng SL, Thompson IM, Platz EA, Xu J.

Prostate. 2016 Sep;76(12):1120-9. doi: 10.1002/pros.23200. Epub 2016 May 16.

Supplemental Content

Support Center